Pachydermoperiostosis Masquerading as Acromegaly

Munira M. Karimova,1 Zamira Yu. Halimova,1 Yulduz M. Urmanova,1 Mártia Korbonits,2 Treena Cranston,3 and Ashley B. Grossman4

1Department of Neuroendocrinology, Center of the Scientific and Clinical Study of Endocrinology, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan 100140; 2Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom; 3Department of Clinical Genetics, Churchill Hospital, and 4Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OXE 7LE, United Kingdom

Context: Acromegaly usually is suspected on clinical grounds. Biochemical confirmation is required to optimize therapy, but there are other differential diagnoses.

Case Description: We describe a 24-year-old Uzbek man who presented with many clinical symptoms and signs of apparent acromegaly. On examination, the patient showed a rugose folding of his scalp, with the formation of tender, painful, rough skin folds in the parietal-occipital region, resembling cerebral gyri (i.e., cutis verticis gyrata). There was also a thickening and enlargement of the eyelids due to cartilaginous hypertrophy, dystrophic changes of the conjunctiva, and atrophy of the Meibomian glands, with the formation of multiple cysts and granulomas. He perspired excessively. There was thickening of the facial skin, with increased oiliness, increased rugosity, and seborrheic dermatitis. The skin over the hands was thick and apparently fixed to the underlying tissues. However, the patient had a low-normal insulin-like growth factor-1 level. More detailed analysis revealed a family history of relatives with similar problems, and certain features were not in keeping with this diagnosis. The disorder pachydermoperiostosis, or pulmonary hypertrophic osteoarthropathy, was suspected, and next-generation screening confirmed that the patient was homozygous for a pathogenic mutation in the SLCO2A1 gene, c.764G>A (p.Gly255Glu).

Conclusion: The condition of pachydermoperiostosis may masquerade as acromegaly but is a genetic disorder, usually autosomal recessive, leading to elevated prostaglandin E2 levels. This is an important, albeit rare, differential diagnosis of acromegaly.

Copyright © 2017 by the Endocrine Society

This article is published under the terms of the Creative Commons Attribution-Non Commercial License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).

Freeform/Key Words: acromegaly, pachydermoperiostosis, pulmonary hypertrophic osteoarthropathy, diagnosis
facial skin, with increased oiliness, increased rugosity, and seborrheic dermatitis. The skin over the hands was thick and apparently fixed to the underlying tissues, with finger clubbing (Fig. 2). On the abdomen were multiple scattered café-au-lait patches.

A diagnosis of acromegaly was suspected. Results of routine baseline investigations were normal, but the serum insulin-like growth factor-1 level, 115 μg/L, was below the normal range for his age (normal 95% confidence limits, 219 to 644 mg/L), and a random growth hormone level was 2.2 μg/L, suggesting that a diagnosis of acromegaly was extremely unlikely [1]. However, the highly rugose nature of his facial and scalp skin, and the presence of finger clubbing suggested the alternative diagnosis of pachydermoperiostosis, also known as hypertrophic pulmonary osteoarthropathy (primary hypertrophic osteoarthropathy autosomal recessive 2, PHOAR2) [2]. Therefore, blood was collected for germline testing of the \textit{SLCO2A1} and \textit{HPGD} genes by next-generation sequencing and dosage analysis (Leeds Genetics Laboratory, Leeds, UK). The patient was homozygous for a pathogenic \textit{SLCO2A1} mutation, c.764G>A (p.Gly255Glu), thus confirming the diagnosis as pachydermoperiostosis. On further questioning, the patient stated that both his maternal and paternal grandfathers had a similar appearance, with thick furrowing of the face and enlargement of their hands and feet, but milder than his, as did his mother’s brother. His parents were unrelated and he had two unaffected siblings. Family members were not available for further verification.

Pachydermoperiostosis has an autosomal recessive inheritance with variable, usually postpubertal, expressivity. The male-to-female ratio of the condition among patients is approximately 8:1. The onset of disease is gradual, with the first signs appearing during puberty, and the full syndrome is usually formed by approximately 20 to 30 years of age. Morphologically, the disease is characterized, above all, by the massive growth of the fibrillar structures of the dermis and subcutaneous tissue with ingrowths of fibrous
connective tissue in the underlying tissues, which causes intimate cohesion of skin. The epidermis is not markedly abnormal, but the dermis becomes thickened with increasing collagen and elastin fibers, marked proliferation of fibroblasts, and small perivascular and perifollicular lymphohistiocytic infiltrates; the ostia of hair follicles become expanded and contain accumulations of horny masses. The number of mature sweat and sebaceous glands substantially increases and sometimes hyperplasia and/or hypertrophy of glandular cells can be seen. Some bones undergo periosteal ossification, with a diffuse layering of osteoid tissue over the cortex. Changes affecting joints include hyperplasia of superficial synovial cells and marked thickening of the walls of small blood vessels because of fibrosis. The pathologic processes also involve all types of vessels, with marked fibrosis in the walls of blood vessels and involvement of the vasculature of the internal organs. Some patients develop myelofibrosis (the full blood cell count in this patient was normal).

Biochemically, the two major genetic lesions both lead to an increase in prostaglandin E2, either by decreased degradation due to enzymatic loss (*HPGD* mutations) [3, 4] or a transporter defect (with *SLCO2A1* mutations) [5]; this excess can be detected in the urine of affected patients. Previous case reports have been published, but few present confirmatory genetic data [6–14].

There are few data on the long-term effects of the disorder other than the chronic effects of the articular disease; however, the association with myelofibrosis is likely to reduce life expectancy, although this has not been quantified. There have been attempts at pharmacotherapy, with some evidence of clinical improvement in certain symptoms with nonsteroidal anti-inflammatory agents [15]. There is often evidence of consanguinity, as for other autosomal recessive diseases.

In summary, we present the images of a patient initially misdiagnosed with acromegaly and who was shown to have pachydermoperiostosis. Endocrinologists should be aware of this rare but important differential diagnosis.
Acknowledgments

Address all correspondence to: Ashley B. Grossman, OCDEM, Churchill Hospital, Oxford OX3 7LE, UK. E-mail: ashley.grossman@ocdem.ox.ac.uk.

Disclosure Summary: The authors have nothing to disclose.

References and Notes

1. Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA; Endocrine Society. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
2. Saigal R, Chaudhary A, Pathak P, Singh A, Gupta D, Tank ML. Pachydermoperiostosis. J Assoc Physicians India. 2016;64(3):88–89.
3. Uppal S, Diggle CP, Carr IM, Fishwick CW, Ahmed M, Ibrahim GH, Helliwell PS, Latos-Bielenińska A, Phillips SE, Markham AF, Bennett CP, Bonthron DT. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet. 2008;40(6):789–793.
4. Zhang Z, Xia W, He J, Zhang Z, Ke Y, Yue H, Wang C, Zhang H, Gu J, Hu W, Fu W, Hu Y, Li M, Liu Y. Exome sequencing identifies SLC02A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet. 2012;90(1):125–132.
5. Diggle CP, Parry DA, Logan CV, Laissue P, Rivera C, Restrepo CM, Fonseca DJ, Morgan JE, Allanore Y, Fontenay M, Wipf J, Varret M, Gibault L, Dalantaevea N, Korbonits M, Zhou B, Yuan G, Harifi G, Cefle K, Palanduz S, Akoglu H, Zwiernizneck PJJ, Lichtenbelt KD, Aubry-Rozier B, Superti-Furga A, Dallapiccola B, Accadia M, Brancati F, Sheridan EG, Taylor GR, Carr IM, Johnson CA, Markham AF, Bonthron DT. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat. 2012;33(8):1175–1181.
6. Rahaman SH, Kandasamy D, Jyotsna VP. Pachydermoperiostosis: incomplete form, mimicking acromegaly. Indian J Endocrinol Metab. 2016;20(5):730–731.
7. Sharma ML, Singh Y, Garg MK, Mishra S. Pachydermoperiostosis - mimic to acromegaly. Med J Armed Forces India. 2015;71(Suppl 1):S187–S189.
8. Shimizu C, Kubo M, Kijima H, Uematsu R, Sawamura Y, Ishizu A, Koike T. A rare case of acromegaly associated with pachydermoperiostosis. J Endocrinol Invest. 1999;22(5):386–389.
9. Singh GR, Menon PS. Pachydermoperiostosis in a 13 year-old boy presenting as an acromegaly-like syndrome. J Pediatr Endocrinol Metab. 1995;8(1):51–54.
10. Stoker DJ. Pachydermoperiostosis mimicking acromegaly. J R Soc Med. 1992;85(5):306.
11. Maby IR, Wiggins J. Pachydermoperiostosis mimicking acromegaly. J R Soc Med. 1992;85(1):46–47.
12. Donnelly S, Sugrue D. It looks like acromegaly [sic] but it is not. Ir J Med Sci. 1991;160(1):8–9.
13. Harbison JB, Nice CM, Jr. Familial pachydermoperiostosis presenting as an acromegaly-like syndrome. Am J Roentgenol Radium Ther Nucl Med. 1971;112(3):532–536.
14. Chakraborty PP, Bhattacharjee R, Mukhopadhyay S, Chowdhury S. Pseudoacromegaly in pachydermoperiostosis [published online ahead of print February 17, 2016]. BMJ Case Rep. doi:10.1136/bcr-2016-214624
15. Li ZT, Wang D, Wang S. Successful treatment of pachydermoperiostosis with etoricoxib in a patient with a homozygous splice-site mutation in the SLC02A1 gene [published online ahead of print February 15, 2016]. Br J Dermatol. doi:10.1111/bjd.14480.